The FDA has approved Perjeta (pertuzumab), in combination with Herceptin (trastuzumab) and chemotherapy for adjuvant treatment for a certain type of early breast cancer.
Indications: Perjeta is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.
Dosage and administration: Administer by intravenous infusion postoperatively every 3 weeks for a total of 1 year (up to 18 cycles).
Efficacy and safety: Approval is based on results of a phase 3 study showing that the combination significantly reduced the risk of invasive breast cancer recurrence or death by 18% vs trastuzumab and chemotherapy alone.
Side effects/risks: The most common adverse reactions are diarrhea, nausea, alopecia, fatigue, peripheral neuropathy, and vomiting.
FDA Approves Genentech’s Perjeta (pertuzumab) for Adjuvant Treatment of Specific Type of Early Breast Cancer [news release]. South San Francisco, CA: Genentech, Inc. December 20, 2017. https://www.businesswire.com/news/home/20171220006056/en/FDA-Approves-Ge.... Accessed December 31, 2017.
Perjeta [package insert]. South San Francisco, CA: Genentech, Inc., 2017. https://www.gene.com/download/pdf/perjeta_prescribing.pdf. Accessed December 31, 2017.
This Week's Must Reads
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Watchful waiting in follicular lymphoma, Davies GA et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 28. doi: 10.1016/j.clml.2018.08.015
ASCO Guideline on Alcohol Consumption and Cancer, J Clin Oncol; 2018 Jan; LoConte, Brewster, et al
Cochrane On Bisphosphonates for Prostate Cancer, Cochrane; 2017 Dec 26; Macherey, Monsef, et al
Cochrane on Vaccine-Based Immunotherapy for NSCLC, Cochrane; 2017 Dec 16; Zhu, Li, Tiselius, et al
Must Reads in Breast Cancer
Stereotactic Radiotherapy System Approved For BC, FDA news release; 2017 Dec 22
Perjeta Approved for Certain Type of Early BC, Genentech news release; 2017 Dec 20
Cochrane on Bisphosphonates for Breast Cancer, Cochrane; 2017 Oct 30; O'Carrigan, Wong, et al
ASCO Updates Guideline on Role of BMAs in BC, J Clin Oncol; ePub 2017 Oct 16; Van Poznak, et al
This Assay Altered Treatment in Patients with BC, JAMA Oncol; ePub 2017 Oct 26; Tsai, Lo, et al